financetom
Business
financetom
/
Business
/
Healthpeak, Janus Living Price Upsized $840 Million IPO
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Healthpeak, Janus Living Price Upsized $840 Million IPO
Mar 19, 2026 2:39 PM

05:13 PM EDT, 03/19/2026 (MT Newswires) -- Healthpeak Properties ( DOC ) and Janus Living said Thursday they priced Janus Living's initial public offering of 42 million class A-1 common shares at $20 each.

Janus Living granted underwriters a 30-day option to purchase up to an additional 6.3 million shares.

The shares are expected to start trading on the NYSE on Friday under the ticker JAN and the IPO is slated to close Monday.

Janus Living plans to use the proceeds for acquisition and investment opportunities and for general corporate purposes.

Following the offering, Healthpeak will own about 214.7 million shares of Janus Living, representing roughly 83.6% voting interest, or 81.6% if the underwriters' option is fully exercised.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
AbbVie Unit Says US FDA Approves Botox Cosmetic as Treatment for Adults With Moderate to Severe Platysma Bands
AbbVie Unit Says US FDA Approves Botox Cosmetic as Treatment for Adults With Moderate to Severe Platysma Bands
Oct 21, 2024
07:57 AM EDT, 10/21/2024 (MT Newswires) -- AbbVie's ( ABBV ) Allergan Aesthetics unit said Monday the US Food and Drug Administration has approved its Botox Cosmetic brand of onabotulinumtoxinA to treat adult patients with moderate to severe platysma bands. Platysma bands connect the jaw and neck, and the cosmetic treatment is intended to improve the appearance of moderate to...
Gilead Sciences, Merck Say Phase 2 Study for HIV Treatment Combination Meets New Endpoints
Gilead Sciences, Merck Say Phase 2 Study for HIV Treatment Combination Meets New Endpoints
Oct 21, 2024
07:56 AM EDT, 10/21/2024 (MT Newswires) -- Gilead Sciences ( GILD ) and Merck ( MRK ) said Saturday that their phase 2 study evaluating the combination therapy of islatravir and lenacapavir as a potential treatment for HIV met its secondary endpoints. The combination therapy showed a 94% rate of viral suppression in the participants, the companies said. It was...
Nigeria approves Exxon-Seplat $1.28 billion deal, oil regulator says
Nigeria approves Exxon-Seplat $1.28 billion deal, oil regulator says
Oct 21, 2024
ABUJA, Oct 21 (Reuters) - Nigeria has approved the sale of Exxon Mobil Corp's ( XOM ) onshore assets to Seplat Energy , the chief executive officer of the country's upstream regulator said on Monday, more than two years after the $1.28 billion deal was first agreed. ...
Market Chatter: Banco Bilbao Vizcaya Shareholder GQG Partners Sells Stake Over Banco Sabadell Bid
Market Chatter: Banco Bilbao Vizcaya Shareholder GQG Partners Sells Stake Over Banco Sabadell Bid
Oct 21, 2024
07:57 AM EDT, 10/21/2024 (MT Newswires) -- Banco Bilbao Vizcaya Argentaria ( BBVA ) shareholder GQG Partners sold its stake in the bank as it opposed BBVA's hostile takeover bid for rival Banco Sabadell, the Financial Times reported Sunday, citing unnamed sources familiar with the matter. The report said GQG Partners was among the top five BBVA shareholders but no...
Copyright 2023-2026 - www.financetom.com All Rights Reserved